Abstract
Purpose
BRAF G469A is a missense mutation within exon 11 of the BRAF gene resulting in a constitutively activated enzyme frequently associated with MAP kinase cascade signaling activation. No evidence currently exists about its role in determining sensitivity/resistance to BRAF inhibitors, utilized in the treatment of patients carrying BRAF V600 mutations, and to chemotherapy. The newly established metastatic melanoma (MM) cell line MO-1 was characterized for its sensitivity to vemurafenib and nab-paclitaxel, both already utilized for the treatment of MM.
Methods
All analyses were carried out by comparing results with those found in MM cells wild type for BRAF or mutated in V600. In addition, cellular effectors were investigated by ELISA kits, western blotting and flow cytometry.
Results
The exposure to vemurafenib inhibited MO-1 cell proliferation at concentrations similar to those obtained in vemurafenib-resistant melanoma models, and an explanation of this sensitivity is the strong activation of Erk1/2 and the low expression of MITF. Nab-paclitaxel strongly reduced proliferation of MO-1 cells perhaps for the very low expression level of PMEL17, transcriptionally regulated by MITF and negatively involved in determining sensitivity to taxanes.
Conclusions
Thus, the mutation BRAF G469A in MM might be related to a weak effectiveness of therapy with BRAF inhibitors and a promising therapeutic approach may be with nab-paclitaxel.
This is a preview of subscription content, log in via an institution to check access.
References
Tentori L, Lacal PM, Graziani G (2013) Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci 34:656–666. doi:10.1016/j.tips.2013.10.003
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867
Kinno T, Tsuta K, Shiraishi K, Mizukami T, Suzuki M, Yoshida A, Suzuki K, Asamura H, Furuta K, Kohno T, Kushima R (2014) Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Ann Oncol 25:138–142. doi:10.1093/annonc/mdt495
Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046–2051. doi:10.1200/JCO.2010.33.1280
Flaherty KT, McArthur G (2010) BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116:4902–4913. doi:10.1002/cncr.25261
Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M (2011) Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J Clin Endocrinol Metab 96:E19–E30. doi:10.1210/jc.2010-1071
Zanna P, Maida I, Turpin Sevilla MC, Susca FC, Filotico R, Arciuli M, Cassano N, Vena GA, Cicero R, Guida G (2011) Molecular characterization of novel melanoma cell lines. J Biol Regul Homeost Agents 25:239–247
Zanna P, Maida I, Grieco C, Guida S, Turpin Sevilla MC, De Summa S, Tommasi S, Vena GA, Filotico R, Guida G (2013) Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins. J Biol Regul Homeost Agents 27:131–141
Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A (2013) Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol 7:308–322. doi:10.1016/j.molonc.2012.10.002
Azzariti A, Colabufo NA, Berardi F, Porcelli L, Niso M, Simone GM, Perrone R, Paradiso A (2006) Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther 5:1807–1816
Porcelli L, Guida G, Quatrale AE, Cocco T, Sidella L, Maida I, Iacobazzi RM, Ferretta A, Stolfa DA, Strippoli S, Guida S, Tommasi S, Guida M, Azzariti A (2015) Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J Transl Med 13:26. [Epub ahead of print]
Velho TR (2012) Metastatic melanoma—a review of current and future drugs. Drugs Context 2012:212242. doi:10.7573/dic.212242 (eCollection 2012)
Rajput S, Volk-Draper LD, Ran S (2013) TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12:1676–1687. doi:10.1158/1535-7163.MCT-12-1019
Li S, De Souza P (2011) Ras isoprenylation and pAkt inhibition by zoledronic acid and fluvastatin enhances paclitaxel activity in T24 Bladder cancer cells. Cancers (Basel) 3:662–674. doi:10.3390/cancers3010662
Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE (2003) MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 163:333–343
Hertzman Johansson C, Azimi A, Frostvik Stolt M, Shojaee S, Wiberg H, Grafström E, Hansson J, Egyházi Brage S (2013) Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines. Melanoma Res 23:360–365
Acknowledgments
We thank Dr. I. Maida and Dr. S. Strippoli for collaboration in protein analysis and in patient’s follow-up information, respectively.
Conflict of interest
The authors have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Porcelli, L., Guida, G., Tommasi, S. et al. Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. Cancer Chemother Pharmacol 76, 433–438 (2015). https://doi.org/10.1007/s00280-015-2796-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2796-6